MAP2K7 and Familial prostate cancer: Results of the combination of an mTOR inhibitor with a MEK inhibitor in the transgenic NKx3. 1-PTEN murine prostate cancer model further supports the rationale for a combined approach in prostate cancer [14] therapy.